Author name: Yali Friedman

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case
Go to paperABSTRACT: …

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cell therapy: European legal and regulatory implications
Go to paperABSTRACT: This paper reviews some of the legal and regulatory considerations that may a…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioterrorism and bioethics: Challenges for industry, government and society
Go to paperABSTRACT: The emerging threat of bioterrorism raises important chall…

This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s

I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…

The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers:

Ihave had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that emerging economies wish to develop ‘a biotechnology industry like the United States.’ I generally temper these ambitions by explaining that the United States does not have a biotechnology industry per se, but rather a handful of states have very strong biotechnology concentrations and many other states are still trying to build their domestic biotechnology industries. So the lesson for many emerging economies is to set ambitions at the US-state level rather than the US-national level. Furthermore, I also caution against aiming for drug development. Drug development is extremely expensive and risky—focusing on domestic agricultural or industrial biotechnology opportunities may be a better option.

In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and d…

Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level. Several recent developments may signal the arrival of a more positive venture-funding environment for life sciences and health technology enterprises, including the development of the Canadian government’s C$400 million Venture Capital Action Plan; pharmaceutical companies electing to establish or investing in venture funds and providing strategic support to early-stage ventures, including through the creation of research centres; and recent successful liquidity events for venture investors.